Article
The RheumNow faculty reporters have been scouring the meeting and online presentations to find the best abstracts from ACR22. Here are some of their choice abstracts reported today on day 1 of ACR 2022 (#ACRbest).
All News
Article
Is patient-administered cervical cancer screening an option for women with SLE? Should I prescribe estrogen containing contraceptives to SLE women with APL antibodies? What complications should I be aware of in pregnant women with SLE? Here are three abstracts that provide insight.
Article
In abstract #0327 presented during the poster session on Saturday, Dr. Ai Li Yeo and colleagues investigated the usefulness of serial anti-dsDNA testing in predicting flares among SLE patients who have persistently positive anti-dsDNA titers.
Article
Recently the FDA approved deucravacitinib, a highly selective TYK2 inhibitor for psoriasis. Trials are positive in psoriatic arthritis and a phase II study in SLE. What about the effects? Presentations from the ACR22 meeting may provide answers.
Eric Dein
Tweet
Abst0338 #ACR22 Transition from CLE to SLE
324 cases of incident cutaneous lupus, mean f/u 8 years
26 pts developed SLE. 5.2% transition by 5 years, <3% risk every 5 yrs from 5-20 years
Risk factors: SCLE, younger age, recent diagnosis
@RheumNow #ACRBest https://t.co/JFcUIkfA9n
Catherine Sims, MD
Tweet
What has changed since the 2020 @ACRheum #reproductive guidelines?
Abstract #1717 425 SLE/RA patients:
📍 significant improvement in pre-#pregnancy counseling and discussions in reproductive goals
📍No improvements in birth control use or documentation
TheDaoIndex
Tweet
#RheumPearls: Check APLs in all SLE pts because they influences contraceptive choice, postpartum/surgery anticoag prophylx, and HRT counseling
Dr. J Kolfenbach #ACR22 @rheumnow https://t.co/Hnrh4NhmBj
sheila
Tweet
P hoc analysis by Dr AGomez et al fr 4 Ph3 RCTs of BEL in #lupus investigated predictors of renal flares
📌Adjusted:⬇️c3, plasma alb & proteinuria levels at BL
📌Non-adj: antidsDNA+, antiSm+ addt'l predictors
🧐p alb & antiSm+ potential predictors?
#ACR22 @RheumNow ABST#540 https://t.co/EYcD7pDYQe
Mike Putman
Tweet
Nice #SLE validation study. This kind of work is (1) time intensive and (2) thankless!
It's not flashy but it winds up being the backbone/foundation for many subsequent studies
Need more in other diseases, including sarcoidosis and myositis! @DidemSayginMD
#ACR22 @RheumNow https://t.co/64z7DBFCnX
Eric Dein
Tweet
Ab0349 #ACR22 BEL vs AZA ifn risks in non-renal SLE
BEL: lower risk of severe ifn (HR 0.81) and hospitalization for ifn (HR 0.73) through 5 yrs
Challenge to interpret data as 56% of patients were on glucocorticoids and other anti-rheumatic meds
@RheumNow https://t.co/a0tNFn5Wqr
Janet Pope
Tweet
Is it the medication or behaviour that increases mortality? #SLICC grp showed in #SLE severe non-adherence to #HCQ in Yr 1 of #lupus = 3 poor outcomes -more 1 flares, 2 damage, 3 5yr-death. Surrogate of other poor health behaviours and/or HCQ? abst#0343 #ACR22 #ACRBest @RheumNow https://t.co/tTRdyti0sf
Eric Dein
Tweet
Ab#0348 #ACR22: Meta-analysis of Belimumab for CLE w or w/o SLE
13 studies included: 70% with low risk of bias
BEL improved clinical response at W52 vs non-users OR 1.44
Decrease risk of severe cutaneous flare OR 0.51
Most studies against placebo group
@RheumNow https://t.co/2bSwNKRHZZ
Md Yuzaiful Md Yusof
Tweet
#ACR22 Year in Review. Dr Varga highlighted work by @Kahlenberglab. Non-lesional skin in patients with #lupus is not normal and is IFN-riched. Also implication for future therapy development to target organ/tissues vs circulation @RheumNow https://t.co/rSnLYrZoMO
Eric Dein
Tweet
Ab0343. #ACR22 Severe non-adherence of HCQ associated with FLARES, DAMAGE and DEATH
7.3% had "severe non-adherence" by HCQ levels
Hazard ratio of flare 3.3, damage 4.26, and death 5.4
Not surprising, but very useful for pt discussion
Checking HCQ levels are helpful!
@Rheumnow https://t.co/S7P9oTPRGJ
TheDaoIndex
Tweet
Dr. C Langford's pick for #YearinReview; she is impressed with the novel mechanistic approaches to #SLE @rheumnow #ACR22. https://t.co/5GrtMYYZSv
Md Yuzaiful Md Yusof
Tweet
#ACR2022 Year in Review. Dr Varga highlighted work by @GeorgeTsokos. In #lupus mice, adding CD38-i in a CD8+ T cell–targeted manner improved effector function, reversed the defects and improved viral clearance. CD38 as a target could reduce infection in SLE @rheumnow https://t.co/XlmvysjkDP
Mike Putman
Tweet
Talking a lot about CAR-T these days! Upcoming @Figure1 newsletter, blog post @RheumNow, and interview w/@MaxKonigMD comping soon!
I'm actually skeptical of this in SLE; are B cells really the answer?
w/better targeting & dx selection, this could be game changing
#ACR22 https://t.co/Z6t99ZIeMy
Md Yuzaiful Md Yusof
Tweet
2022 has been a great year for development of novel therapies in Phase 2 RCTs in #lupus as highlighted by Dr Langford #ACR22 Year In Review. I'd add Deucravacitinib to those lists. Look forward to Phase 3 results soon @RheumNow https://t.co/yH25KFDGdd
Robert B Chao, MD
Tweet
CAR T cell therapy for treatment of lupus
Small sample size of 5 pts, but improvement in all pts, 4 achieving SLEDAI =0
Note - cytokine release syndrome in 3 pts.
Excellent overview of CAR T cell therapy and its complexity!
@RheumNow #ACR22 https://t.co/3PP14tVudb
Eric Dein
Tweet
#acr22 The Rise of JAK in rheumatology
Look for Ab1117 in plenary 2 tomorrow for DEU and SLE
@RheumNow https://t.co/nLpXGyrhfJ
